Ultragenyx Pharmaceutical (NASDAQ:RARE) Given Buy Rating at HC Wainwright

Key Points

• HC Wainwright has reiterated a "Buy" rating for Ultragenyx Pharmaceutical's stock with a target price of $80.00, indicating a potential upside of 153.89%.
• The company's recent earnings report showed that Ultragenyx surpassed analysts' estimates with a revenue of $166.50 million and an earnings per share of ($1.17), a slight improvement from the previous year's EPS of ($1.52).
• Despite the positive ratings from several analysts, the stock has fluctuated recently with a current price around $31.51, significantly lower than the target prices set by analysts.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $80.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 163.94% from the company's current price.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. William Blair began coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Guggenheim reaffirmed a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Finally, Canaccord Genuity Group decreased their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded down $0.92 during mid-day trading on Tuesday, reaching $30.31. The stock had a trading volume of 1,391,015 shares, compared to its average volume of 1,297,833. The business's 50 day moving average is $29.70 and its 200 day moving average is $34.41. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $60.37. The stock has a market cap of $2.92 billion, a P/E ratio of -5.48 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. During the same quarter in the prior year, the company posted ($1.52) earnings per share. The firm's revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president directly owned 73,271 shares of the company's stock, valued at approximately $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently modified their holdings of the business. California State Teachers Retirement System boosted its position in shares of Ultragenyx Pharmaceutical by 0.3% in the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after acquiring an additional 268 shares during the period. GAMMA Investing LLC raised its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Xponance Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 2.8% in the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after purchasing an additional 347 shares in the last quarter. Oak Ridge Investments LLC raised its stake in shares of Ultragenyx Pharmaceutical by 2.3% in the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after purchasing an additional 395 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in shares of Ultragenyx Pharmaceutical by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company's stock valued at $828,000 after purchasing an additional 404 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.